MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$4,424K
Free Cash flow
-$1,759K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from the issuance of co...
Depreciation and amortization
Other current assets
Others
Negative Cash Flow Breakdown
Employee related expenses (less ...
Direct costs and expenses (less ...
Sales and marketing education an...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
26,861
25,555
28,755
59,744
Direct costs and expenses (less employee related expenses and depreciation and amortization)
3,540
2,712
3,438
8,634
Employee related expenses (less share-based compensation expenses)
19,420
19,209
18,121
48,703
Contracted services expenses
1,692
1,689
1,321
5,691
Sales and marketing education and event expenses
2,235
2,211
1,961
5,601
Occupancy and equipment service expenses
974
996
998
3,079
Clinical trials and associated costs
191
638
443
1,287
Depreciation and amortization expense
1,387
1,396
1,387
1,407
Share-based compensation expenses
820
1,115
1,075
3,064
Interest expense
1,982
1,977
2,059
5,657
Change in fair value of warrant liability, net
-
-
0
0
Other segment items
1,893
1,405
1,932
4,750
Net loss
-7,273
-7,793
-3,980
-8,716
Depreciation and amortization
1,387
1,396
1,387
1,407
Accretion of lease right-of-use assets
-
-
19
-29
Reduction (accretion) of lease right-of-use assets
24
19
-
-
Share-based compensation expense
820
1,115
1,075
1,053
Change in fair value of warrant liability, net
-
-
0
0
Provision for credit losses
92
24
71
0
Accrued interest, amortization of debt issuance costs and other
329
332
333
332
Inventory excess and obsolescence
6
20
28
10
Impairment loss on intangible assets
12
5
1
7
Accounts receivable
-294
488
-3,608
5,224
Other current assets
-1,379
1,366
592
-16
Other long-term assets
-1,020
-19
-9
125
Accounts payable and other accrued liabilities
767
-2,344
974
486
Deferred revenue
-47
-766
-1,840
2,128
Current and long-term operating lease liabilities
-372
-341
-315
-224
Net cash, cash equivalents, and restricted cash used in operating activities
-1,562
-10,168
778
-8,879
Purchase of property and equipment
197
81
86
48
Patent costs and intangible asset acquisition, net
57
63
18
19
Net cash, cash equivalents, and restricted cash used in investing activities
-254
-144
-104
-67
Proceeds from the issuance of common stock
6,672
17,214
2,320
5,000
Proceeds from issuance of common stock under employee stock purchase plan
0
354
0
184
Proceeds from term loan and notes payable
-
-
0
0
Proceeds from exercise of stock options
8
1
-
-
Repayment of term loan and notes payable
1
5
5
4
Payment of debt issuance costs
11
28
0
3
Equity financing costs
275
481
344
188
Other
-153
-158
-262
-167
Net cash, cash equivalents, and restricted cash provided by financing activities
6,240
16,897
1,709
4,822
Net increase (decrease) in cash, cash equivalents, and restricted cash
4,424
6,585
2,383
-4,124
Cash, cash equivalents, and restricted cash beginning of period
25,660
19,075
16,692
26,332
Cash, cash equivalents, and restricted cash end of period
30,084
25,660
19,075
16,692
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
issuance of common stock
$6,672K
Proceeds from exercise of
stock options
$8K
Net cash, cash
equivalents, and restricted...
$6,240K
(-36.88%↓ Y/Y)
Canceled cashflow
$440K
Net increase
(decrease) in cash, cash...
$4,424K
(180.20%↑ Y/Y)
Canceled cashflow
$1,816K
Equity financing costs
$275K
Other
-$153K
(60.57%↑ Y/Y)
Payment of debt issuance
costs
$11K
(-59.26%↓ Y/Y)
Repayment of term loan and
notes payable
$1K
(-91.67%↓ Y/Y)
Depreciation and
amortization
$1,387K
(-51.77%↓ Y/Y)
Other current assets
-$1,379K
(-333.65%↓ Y/Y)
Other long-term
assets
-$1,020K
(-20500.00%↓ Y/Y)
Share-based compensation
expense
$820K
(-59.22%↓ Y/Y)
Accounts payable and
other accrued...
$767K
(92.23%↑ Y/Y)
Accrued interest,
amortization of debt issuance...
$329K
(-48.51%↓ Y/Y)
Accounts receivable
-$294K
(72.90%↑ Y/Y)
Provision for credit
losses
$92K
(-15.60%↓ Y/Y)
Reduction (accretion) of
lease right-of-use...
$24K
Impairment loss on
intangible assets
$12K
(-87.88%↓ Y/Y)
Inventory excess and
obsolescence
$6K
(-45.45%↓ Y/Y)
Net cash, cash
equivalents, and restricted...
-$1,562K
(89.70%↑ Y/Y)
Net cash, cash
equivalents, and restricted...
-$254K
(-9.48%↓ Y/Y)
Canceled cashflow
$6,130K
Revenues
$26,861K
Net loss
-$7,273K
(67.77%↑ Y/Y)
Purchase of property and
equipment
$197K
(57.60%↑ Y/Y)
Patent costs and
intangible asset...
$57K
(-46.73%↓ Y/Y)
Canceled cashflow
$26,861K
Current and long-term
operating lease...
-$372K
(-48.80%↓ Y/Y)
Deferred revenue
-$47K
(58.77%↑ Y/Y)
Employee related
expenses (less...
$19,420K
Direct costs and
expenses (less employee...
$3,540K
Sales and marketing
education and event...
$2,235K
Interest expense
$1,982K
Other segment items
$1,893K
Contracted services
expenses
$1,692K
Depreciation and
amortization expense
$1,387K
(-51.77%↓ Y/Y)
Occupancy and equipment
service expenses
$974K
Share-based compensation
expenses
$820K
Clinical trials and
associated costs
$191K
Buy us a coffee
BIODESIX INC (BDSX)
BIODESIX INC (BDSX)